TRX-0237 HBr (LMTX; LMT-X; TRX0237; Leuco-MTx; Hydromethylthionine mesylate; Leucomethylene Blue), the hydrobromide salt of TRX-0237 (in phase III clinical trials), is a novel and potent inhibitor of tau aggregation with potential use for the treatment of Alzheimer's disease (AD) and frontotemporal dementia. Hydromethylthionine showed pharmacological activity on brain structure and function as both monotherapy and as an add-on to symptomatic treatment in certain patients with Alzheimer's disease.

纯度：≥98%

CAS：951131-15-0